News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Carl Zeiss Co. Ltd. Purchases Bio-Rad Laboratories, Inc.'s (BIO) Confocal Microscopy Business


10/19/2005 5:11:33 PM

HERCULES, Calif., May 28 /PRNewswire-FirstCall/ -- Bio-Rad Laboratories, Inc. , a pioneer in developing and commercializing confocal microscopy and multi-photon technology, announced today the sale of its U.K. based confocal microscopy business to Carl Zeiss Jena GMBH, effective June 1, 2004. Terms of the sale have not been disclosed. Carl Zeiss is a world leader in precision optics and engineering with over 150 years of experience.

"We are proud of the many innovations we have made in the areas of confocal and multi-photon microscopy," said Bio-Rad President and CEO Norman Schwartz. "Going forward we believe that customers will be better served by a more specialized microscopy focused business. Carl Zeiss is a leader in this area."

"This strategic move is part of our ongoing investment in enhancing and broadening the application expertise at Carl Zeiss," said Dr. Ulrich Simon, head of the microscopy business group at Carl Zeiss. "The mission is to bring together technological and application know-how to provide support and develop solutions dedicated to the application needs in modern biomedical research."

Bio-Rad Laboratories, Inc. (http://www.bio-rad.com/) is a multinational manufacturer and distributor of life science research products and clinical diagnostics. It is based in Hercules, California, and serves more than 70,000 research and industry customers worldwide through a network of more than 30 wholly owned subsidiary offices. Bio-Rad's confocal microscopy products are manufactured in Hemel Hempstead, U.K.

Various statements made within this press release may constitute "forward- looking statements" for purposes of the Securities and Exchange Commission's "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under the Securities Exchange Act of 1934. The forward- looking statements contained herein involve risks and uncertainties that could cause results to differ materially from the Company's expectations.

Bio-Rad Laboratories, Inc.

CONTACT: Christine Tsingos, Chief Financial Officer, or Ron Hutton,Treasurer, of Bio-Rad Laboratories, Inc., +1-510-724-7000 orinvestor_relations@bio-rad.com; or Jim Sharp, President of Carl ZeissMicroImaging, Inc., +1-914-681-7762 or Jsharp@Zeiss.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES